Please join us at the 7th Annual Lymphoma Symposium organized on August 2, 2025. Outstanding speakers will review the latest data and spark thought provoking discussions.
Registration link: https://t.co/wOOmwifXYD
Liso-cel 2ary CNS lymphoma: Ahmed
- 57 pts, 39 wth active CNSL at infn
- ORR 73%, 12mo PFS 30%, 45% 12mo OS
- no diff if active or not active CNSL
- 16% G3/4 ICANs (?higher than for other liso-cel data)
#ASH24#lymsm
If you see an eligible DLBCL patient in CR, does #CART outperform AutoHCT? Only available data by @CIBMTR@mshadman Reminds you to keep an open mind,
one size does not fit all 🙏🙏 @ASH_hematology for recognizing our work in Press Release #ASH23
Great to contribute to this important study of Mosunetuzumab and Polatuzumab in RR DLBCL. ASH abstract#613 @ash2023. @karmanoscancer. Feel free to check out this simultaneous publication in nature Medicine. https://t.co/9WgoJo6wyr
Time-limited triple therapy leads to high rates of undetectable minimal residual disease and sustained remissions in high-risk CLL. https://t.co/IVpHcHJoWR
Join us tomorrow, Aug 12th, Sat at 7PM CST to chat about how to navigate through Heme-Onc fellowship interviews!!! Thank you @drtulsijose @ascobhsetx for inviting me!
Sign up now:
https://t.co/TOZd2nGfno
S1826- Nivo+ AVD significantly improved PFS compared to BV+AVD and will become a standard of care for advanced Hodgkin lymphoma. The combination was well tolerated and rate of consolidation radiation therapy was considerably low.
Please mark your calendar to attend The 5th Annual Lymphoma Symposium organized by @Dipenkmodi@karmanoscancer to learn about updates in management of various lymphomas.